AR054386A1 - Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina - Google Patents

Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina

Info

Publication number
AR054386A1
AR054386A1 ARP060102422A ARP060102422A AR054386A1 AR 054386 A1 AR054386 A1 AR 054386A1 AR P060102422 A ARP060102422 A AR P060102422A AR P060102422 A ARP060102422 A AR P060102422A AR 054386 A1 AR054386 A1 AR 054386A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
alkoxy
heteroaryl
halogen
Prior art date
Application number
ARP060102422A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR054386A1 publication Critical patent/AR054386A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula (1) y ss N-oxidos, sales, solvatos e isomeros estereoquímicos aceptables desde el punto de vista farmacéutico, donde: Q es CH2 o un enlace directo; G es O, o S; X es N o CH; Z es NH, N8alquilo), o CH2; B es fenilo, cicloalquilo, heteroarilo, un heteroarilo benzo-fusionado de nueve a diez miembros, o un heterociclilo benzo-fusionado de nueve a diez miembros, R1 y R2 se seleccionan en forma independientemente de: (a-1) a (a-6), donde n es 1, 2, 3 o 4; Y es un enlace directo, O, S, NH, o N(alquilo); Ra es alcoxi, fenoxi, heteroarilo sustituido en forma opcional con R5, hidroxilo, alquilamino, dialquilamino, oxazolidinonilo sustituido en forma opcional con R5, pirrolidinonilo sustituido en forma opcional con R5, piperidinonilo sustituido en forma opcional con R5, piperazinil-2-ona sustituida en forma opcional con R5, heterodionilo cíclico sustituido en forma opcional con R5, heterociclilo sustituido en forma opcional con R5, escuarilo sustituido en forma opcional con R5, -COORy, -CONRwRx, -N(Ry)CON(Rw)(Rx), -N(Rw)C(O)ORx, -N(Rw)CORy, -SRy, -SORy, -SO2Ry, -NRwSO2Ry, -NRwSO2Rx, -SO3Ry, -OSO2NRwRx o -SO2NRwRx; Rw y Rx se seleccionan en forma independiente de: H, alquilo, alquenilo, aralquilo o heteroaralquilo, o Rw y Rx pueden tomarse juntos, en forma opcional, para formar un anillo de 5 a 7 miembros, que cntiene en forma opcional un resto con heteroátomo seleccionado de O, NH, N(alquilo), SO, SO2, o S; Ry se selecciona de: H, alquilo, alquenilo, cicloalquilo, fenilo, aralquilo, heteroaralquilo, o heteroarilo; R5 es 1, 2 o 3 sustituyentes selecionados de manera independiente de: halogeno, ciano, trifluorometilo, amno, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, - SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)-alquil C1-4-N(alquilo)2, alquilo, -alquilC1-4-OH, -alquil C1-4-OCH3, -C(O)alquilC1-4-OH, -C(O)alquil C1-4-OCH3, dialquilamino o alquilamino; siempre que el mismo sustituyente R5 no esté presente más de una vez, salvo que dcho sustituyente R5 sea halogeno, hidroxilo, alcoxi o alquilo; Rbb es H, halogeno, alcoxi, dialquilamino, fenilo sustituido en forma opcional con R6, heteroarilo sustituido en forma opcional con R6, piperazinil-2-ona sustituida en forma opcional con R6, imidazolidinil-2-ona sustituida en forma opcional con R6, oxazolidinil-2-ona sustituida en forma opcional con R6, o heterociclilo sustituido en forma opcional con R6; R6 es 1, 2 o 3 sustituyentes seleccionados de manera independiente de: halogeno, ciano, trifluorometilo, amino, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)-alquilC1-4-N(alquilo)2, alquilo, -alquilC1-4-OH, -alquilC1-4-OCH3, -C(O)alquilC1-4- OH, -C(O)alquilC1-4-OCH3, dialquilamino o alquilamino, siempre que el mismo sustituyente R6 no esté presente más de una vez, salvo que dicho sustituyente R6 sea halogeno, hidroxilo, alcoxi o alquilo; Rc es heterociclilo sustituido en forma opcional con R7, o heteroarilo, y R7 es 1, 2 o 3 sustituyentes seleccionados de manera independiente de: halogeno, ciano, trifluorometilo, amino, hidroxilo, heteroarilo, alcoxi, -C(O)alquilo, -SO2alquilo, -C(O)NH(alquilo), -C(O)N(alquilo)2, -C(O)-alquilC1-4- N(alquilo)2, alquilo, -alquilC1-4-OH, -alquilC1-4-OCH3, -C(O)alquilC1-4-OH, -C(O)alquilC1-4-OCH3, dialquilamino o alquilamino, siempre que el mismo sustituyente R7 no esté presente más de una vez, a no ser que dicho sustituyente R7 sea halogeno, hidroxilo, alcoxi o alquilo; R3 es uno o más sustituyentes seleccionados de manera independiente de: H siempre que Rbb no sea H, alquilo, alcoxi, halogeno, amino sustituido en forma opcional con R4, (alquilC1-2-OH, nitro, cicloalquilo sustituido en forma opcional con R4, heteroarilo sustituido en forma opcional con R4, alquilamino, heterociclilo sustituido en forma opcional con R4, alcoxiéter, -O(cicloalquilo), pirrolidinonilo sustituido en forma opcional con R4, fenoxi sustituido en forma opcional con R4, -CN, -OCHF2, -OCF3, -CF3, alquilo halogenado, heteroariloxi sustituido en forma opcional con R4, dialquilamino, -NHSO2alquilo o -SO2alquilo; donde R4 se selecciona de manera independiente de: halogeno, cian, trifluorometilo, amino, hidroxilo, alcoxi, -C(O)alquilo, -CO2alquilo, -SO2alquilo, -C(O)N(alquilo)2, alquilo o alquilamino.
ARP060102422A 2005-06-10 2006-06-09 Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina AR054386A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938405P 2005-06-10 2005-06-10
US73091905P 2005-10-27 2005-10-27

Publications (1)

Publication Number Publication Date
AR054386A1 true AR054386A1 (es) 2007-06-20

Family

ID=37038081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102422A AR054386A1 (es) 2005-06-10 2006-06-09 Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina

Country Status (18)

Country Link
US (1) US8071768B2 (es)
EP (1) EP1893598A1 (es)
JP (1) JP2009501135A (es)
KR (1) KR20080028912A (es)
AR (1) AR054386A1 (es)
AU (1) AU2006257945A1 (es)
BR (1) BRPI0611964A2 (es)
CA (1) CA2611242A1 (es)
CR (1) CR9652A (es)
EA (1) EA200800017A1 (es)
EC (1) ECSP077997A (es)
GT (1) GT200600251A (es)
IL (1) IL187692A0 (es)
NO (1) NO20080174L (es)
PE (1) PE20070014A1 (es)
TW (1) TW200716599A (es)
UY (1) UY29588A1 (es)
WO (1) WO2006135721A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825244B2 (en) * 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US8760507B2 (en) * 2008-08-05 2014-06-24 Inspectron, Inc. Light pipe for imaging head of video inspection device
US20130029978A1 (en) * 2009-12-25 2013-01-31 Mochida Pharmaceutical Co., Ltd. Novel aryl urea derivative
US8883791B2 (en) 2010-09-29 2014-11-11 Intervet Inc. N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases
RU2612972C2 (ru) 2011-07-27 2017-03-14 Аб Сьянс Селективные ингибиторы протеинкиназ
JP6506694B2 (ja) * 2012-11-20 2019-04-24 メリアル インコーポレイテッド 駆虫性化合物及び組成物並びにこれらの使用方法
DK3059227T3 (da) * 2013-10-16 2019-08-26 Fujifilm Corp Salt af en nitrogen-holdig heterocyklisk forbindelse eller krystal deraf, farmaceutisk sammensætning og flt3-hæmmer
JP2016540811A (ja) * 2013-12-20 2016-12-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ Ｎ−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
JP2017538678A (ja) 2014-11-05 2017-12-28 フレクサス・バイオサイエンシーズ・インコーポレイテッドＦｌｅｘｕｓ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ． 免疫調節剤
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
JP6412471B2 (ja) * 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
US20210379052A1 (en) * 2018-09-27 2021-12-09 Shenzhen Chipscreen Biosciences Co., Ltd. Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity
US20220154220A1 (en) * 2018-12-21 2022-05-19 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Small molecules for increasing precise genome editing efficiency

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517005A (en) * 1967-10-26 1970-06-23 Pfizer & Co C Certain 2- and 4-substituted quinazolines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
JPS5976082A (ja) 1982-10-23 1984-04-28 Kyowa Hakko Kogyo Co Ltd 新規なピペリジン誘導体
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
ES2193143T3 (es) * 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
WO1996032907A1 (en) 1995-04-19 1996-10-24 Schneider (Usa) Inc. Drug release coated stent
WO1997028118A1 (en) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Process for preparing anthranilic acids
WO1997038992A1 (en) 1996-04-12 1997-10-23 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyramidine derivatives
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US5869669A (en) * 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
EP0882717B1 (en) * 1996-10-01 2010-09-08 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
EP1047691A1 (en) 1997-12-12 2000-11-02 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
DE19756388A1 (de) * 1997-12-18 1999-06-24 Hoechst Marion Roussel De Gmbh Substituierte 2-Aryl-4-amino-chinazoline
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
WO2001032632A2 (en) 1999-11-01 2001-05-10 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
AU2001293207A1 (en) 2000-08-18 2002-03-04 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
EP1309569B1 (en) 2000-08-18 2010-10-06 Millennium Pharmaceuticals, Inc. N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamide derivatives as PDGFRs inhibitors
ATE303998T1 (de) 2000-10-17 2005-09-15 Merck & Co Inc Oral aktive salze mit tyrosinkinaseaktivität
MXPA03004245A (es) 2000-12-12 2003-09-22 Neurogen Corp Espiro[isobenzofuran-1,4'piperidin]-3-onas y 3h-espiroisobenzofuran-1,4'-piperidinas.
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
RU2337692C3 (ru) 2001-10-30 2020-11-09 Новартис Аг Производные стауроспорина в качестве ингибиторов активности рецепторной тирозинкиназы flt3
IL162203A0 (en) 2001-12-27 2005-11-20 Theravance Inc Indolinone derivatives useful as protein inase inhibitors
EP1474420B1 (en) 2002-02-01 2012-03-14 AstraZeneca AB Quinazoline compounds
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CA2489560A1 (en) 2002-06-27 2004-01-08 Schering Aktiengesellschaft Substituted quinoline ccr5 receptor antagonists
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2004016597A2 (en) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
BR0316229A (pt) 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
WO2004058749A1 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
AU2003299791A1 (en) 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
KR101223914B1 (ko) 2003-11-21 2013-01-18 어레이 바이오파마 인크. Ａｋｔ 단백질 키나제 억제제
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis

Also Published As

Publication number Publication date
AU2006257945A1 (en) 2006-12-21
TW200716599A (en) 2007-05-01
EP1893598A1 (en) 2008-03-05
IL187692A0 (en) 2008-08-07
KR20080028912A (ko) 2008-04-02
GT200600251A (es) 2007-01-12
WO2006135721A1 (en) 2006-12-21
US20060281772A1 (en) 2006-12-14
JP2009501135A (ja) 2009-01-15
PE20070014A1 (es) 2007-03-08
NO20080174L (no) 2008-02-19
ECSP077997A (es) 2008-01-23
CR9652A (es) 2008-09-09
UY29588A1 (es) 2006-10-02
CA2611242A1 (en) 2006-12-21
BRPI0611964A2 (pt) 2009-01-27
US8071768B2 (en) 2011-12-06
EA200800017A1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
AR054386A1 (es) Moduladores de quinasas con estructuras de alquiloquinolina y alquilquinazolina
AR053895A1 (es) Aminopirimidinas como moduladores de quinasas
AR054388A1 (es) Aminopirimidinas como moduladores de quinasas
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
CO6251261A2 (es) Derivados de 1- 82-amino-2-oxoalquil)-n(1h-indazol-5-il)pirrolidina-3-carboxamida
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
CO6150144A2 (es) Inhibidores de proteina tirosina fosfatasa humana y metodos de uso
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR054524A1 (es) Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
AR072779A1 (es) Inhibidores macrociclicos de la replicacion del virus de la hepatitis c
TW200833251A (en) Pesticidal compositions
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR054551A1 (es) Metodos para la neuroproteccion
ME00443B (me) Kristalni oblik tercijalne butilaminske soli perindoprila
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
NO20062549L (no) Substituerte arylpyrazoler anti-paresittmidlert
AR047537A1 (es) Piridazinonaureas como antagonistas de integrinas
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal